Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

NEW HAVEN, Conn., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals,
Inc. (Nasdaq:ACHN) today reported progress on the Company's portfolio of
proprietary compounds for the treatment of chronic hepatitis C (HCV) and
outlined its 2014 milestones.

"We believe that we have the broad portfolio of HCV compounds necessary to
succeed in achieving our primary goal of developing commercially competitive
short duration therapies for the treatment of HCV that are once-daily and
ribavirin-free. With the emerging safety and in vitro data on ACH-3422, a
uridine nucleotide inhibitor of NS5B polymerase, and the 12-week clinical
activity reported with ACH-3102, our Phase 2, pan-genotypic, second-generation
NS5A inhibitor, we believe that our HCV compounds are well-positioned to
achieve positive results in the clinical studies we plan to initiate
throughout 2014," commented Dr. Milind Deshpande, President and Chief
Executive Officer of Achillion. "With our 2013 year-end cash balance projected
to exceed $150 million, we believe we have sufficient capital to fund our
operations into 2016 and achieve a number of value-creating milestones
throughout this year with our HCV assets."

2014 Milestones

  oACH-3422: HCV Nucleotide NS5B Polymerase Inhibitor

  -To date, all of the Company's preclinical studies support the advancement
  of ACH-3422 into clinical trials. Achillion expects to initiate a Phase 1
  first-in-human trial ex-US during the second quarter of 2014, subject to
  regulatory approval, followed by a Phase 1 proof-of-concept trial in
  mid-2014. Achillion anticipates reporting initial results from HCV-infected
  patients in the third quarter of 2014.

  oACH-3102 + sofosbuvir

  -Achillion plans to initiate a pilot Phase 2 study early in the second
  quarter of 2014 evaluating the combination of ACH-3102, a second-generation
  NS5A inhibitor in Phase 2, with sofosbuvir in treatment-naive HCV patients
  over treatment durations of 8 weeks or less. The study aims to optimize the
  use of ACH-3102 in nucleotide-based regimens and to expedite the development
  of the combination of ACH-3102 and ACH-3422.

  oACH-3422 + ACH-3102 ± NS3/4A protease inhibitor

  -Achillion anticipates the initiation of an all-oral Phase 2 combination
  study evaluating ACH-3422 by year-end 2014, and anticipates the initiation
  of a Phase 2 combination study evaluating ACH-3422 and ACH-3102, with and
  without an Achillion NS3/4A protease inhibitor, in treatment-naive HCV
  patients over treatment durations of 8 weeks or less in early 2015.

  oACH-3102 + ACH-2684

  -Achillion intends to evaluate the combination of its NS5A inhibitor
  ACH-3102, and next-generation NS3/4A protease inhibitor, ACH-2684, in a
  Phase 1 drug-drug interaction study that is expected to begin in the first
  quarter of 2014.

  -The Company also plans to initiate a proof-of-concept study evaluating
  this combination in genotype 1b HCV-infected patients over a treatment
  duration of 8 weeks in mid-2014 to enable future combination studies.

Sovaprevir: NS3/4A Protease Inhibitor

  -Achillion is preparing a complete response package on the previously
  disclosed sovaprevir clinical hold and anticipates a response from the FDA
  by the end of the first half of 2014.

  -In the ongoing Phase 2 -007 trial evaluating 12-week treatment with
  sovaprevir, ACH-3102, and ribavirin in combination, to date all patients
  with chronic genotype 1b HCV infection have maintained 100% virologic
  response despite the presence of multiple resistant mutations at baseline in
  the NS5A protein. As anticipated by the viral breakthroughs previously
  reported in genotype 1a patients, the combination of sovaprevir and ACH-3102
  is not being pursued as a treatment for chronic genotype 1a HCV infection.
  Achillion intends to submit these study results for presentation at a
  scientific conference in 2014.

"We are very pleased with the overall progress across our broad HCV portfolio.
We believe that the clinical strategy outlined for 2014 will enable us to move
toward delivering commercially competitive treatment regimens for HCV,"
commented Dr. David Apelian, M.D., Ph.D., Chief Medical Officer at Achillion.
"Furthermore, with Achillion's broad portfolio of assets, we believe that the
addition of an NS5B nucleotide inhibitor, such as ACH-3422, could achieve very
competitive cure rates across broad patient populations with a treatment
regimen of 8 weeks or less."

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing
important new treatments to patients with infectious disease. Achillion's
discovery, clinical development, and commercial teams have advanced multiple
novel product candidates with proven mechanisms of action into studies and
toward the market. Achillion is focused on solutions for the most challenging
problems in infectious disease including HCV and resistant bacterial
infections. For more information on Achillion Pharmaceuticals, please visit
www.achillion.com or call 1-203-624-7000.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to
risks, uncertainties and other important factors that could cause actual
results to differ materially from those indicated by such forward-looking
statements, including statements with respect to: the potential benefits and
prospects for Achillion's portfolio of HCV compounds; expectations regarding
clinical study results in 2014; Achillion's projected year-end cash balance,
its expectations as to the period in which such cash will be available to fund
its operations, and the prospects for such cash enabling it to achieve
milestones; the Company's 2014 milestone goals, including with respect to
advancing compounds into and through clinical development and obtaining data
readouts from trials of its compounds; and its plans and timing with respect
to the FDA clinical hold on sovaprevir. Achillion may use words such as
"expect," "anticipate," "project," "intend," "plan," "aim," "believe," "seek,"
"estimate," and "may" and similar expressions to identify such forward-looking
statements. Among the important factors that could cause actual results to
differ materially from those indicated by such forward-looking statements are
risks relating to, among other things Achillion's ability to: demonstrate in
any current and future clinical trials the requisite safety, efficacy and
combinability of its drug candidates; advance the preclinical and clinical
development its drug candidates, including ACH-3422, ACH-3102 and ACH-2684,
under the timelines it projects in current and future clinical trials;
satisfactorily respond to the clinical hold placed on sovaprevir by the FDA;
obtain and maintain necessary regulatory approvals; obtain and maintain patent
protection for its drug candidates and the freedom to operate under third
party intellectual property; establish commercial manufacturing arrangements;
identify, enter into and maintain collaboration agreements with appropriate
third-parties; compete successfully with other companies that are seeking to
develop improved therapies for the treatment of HCV; manage expenses; manage
litigation; raise the substantial additional capital needed to achieve its
business objectives; and successfully execute on its business strategies.
These and other risks are described in the reports filed by Achillion with the
U.S. Securities and Exchange Commission, including its Quarterly Report on
Form 10-Q for the fiscal quarter ended September 30, 2013 and its subsequent
SEC filings.

In addition, any forward-looking statement in this press release represents
Achillion's views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent date. Achillion
disclaims any duty to update any forward-looking statement, except as required
by applicable law.

CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         gschulman@achillion.com
        
         Media:
         Emily Johnson
         Ogilvy PR
         Tel. (212) 880-5316
         emily.johnson@ogilvy.com
        
         Investors:
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         mfenton@achillion.com
        
         Investors:
         Lee Stern
         The Trout Group, LLC
         Tel. (646) 378-2922
         lstern@troutgroup.com

Achillion Pharmaceuticals logo
 
Press spacebar to pause and continue. Press esc to stop.